{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:26Z","timestamp":1787772386423,"version":"build-2784847793"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Mucormycosis is a rare but serious fungal infection which has dramatically increased in post-COVID patients. There is a paucity of safety data on amphotericin B (amphoB) used for mucormycosis treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>The objective of this prospective, observational, active safety surveillance study was to evaluate the safety profile of amphoB in a cohort of hospitalized patients who were on the drug for suspected mucormycosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>All suspected adverse drug reactions (ADRs) in hospitalized mucormycosis patients who had received amphoB were analyzed. The nature, severity, outcome of the ADRs were recorded and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of the 77 patients enrolled, 70% had documented history of prior COVID-19 infection. 96% had comorbidities, the most common being diabetes. Majority received conventional amphotericin B deoxycholate formulation. 97% experienced at least one suspected ADR and the median ADR\/patient was 3. Out of 214 ADRs, 91 were serious but there were no ADR-related deaths. The most common ADRs were hypokalemia (31.78%), infusion-related reactions (22.43%), and anemia (17.29%). Thirty-three patients had serum potassium &lt;2.5 mEq\/L, while 11 had serum magnesium &lt;1.25 mg\/dL. Doubling of pretreatment creatinine level was noted in 15 patients. Seventy percent ADRs were of \u201cpossible\u201d category as per the World Health Organization Uppsala Monitoring Centre categorization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>AmphoB deoxycholate use in mucormycosis patients was associated with a high incidence of electrolyte abnormalities and infusion-related reactions. All ADRs subsided with medical management and none were fatal. The safety data generated from this study may be useful in resource-limited settings where the far more expensive liposomal formulation is not being used.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_474_22","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:47:00Z","timestamp":1716479220000},"page":"417-422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacovigilance study of amphotericin B for mucormycosis in post-COVID and non-COVID patients at a tertiary care hospital in Eastern India"],"prefix":"10.4103","volume":"54","author":[{"given":"Suparna","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biman Kanti","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240903","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R2-4-20240903","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi (Basel"},{"key":"R3-4-20240903","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1017\/S0022215121000992","article-title":"Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum","volume":"135","author":"Sharma","year":"2021","journal-title":"J Laryngol Otol"},{"key":"R4-4-20240903","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R6-4-20240903","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1093\/cid\/ciz091","article-title":"Pharmacology of liposomal amphotericin B: An introduction to preclinical and clinical advances for treatment of life-threatening invasive fungal infections","volume":"68","author":"Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R13-4-20240903","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"R14-4-20240903","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bcp.13521","article-title":"Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations","volume":"84","author":"Andrew","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R15-4-20240903","first-page":"25","article-title":"Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital","volume":"27","author":"Quinteros","year":"2010","journal-title":"Rev Chilena Infectol"},{"key":"R16-4-20240903","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/jcph.772","article-title":"Adverse drug reactions in patients receiving systemic antifungal therapy at a high-complexity hospital","volume":"56","author":"de Souza","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R17-4-20240903","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40360-017-0186-x","article-title":"Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients","volume":"18","author":"V\u00e1zquez-Alvarez","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"R18-4-20240903","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/0253-7613.75664","article-title":"Adverse drug reaction monitoring in psychiatry out-patient department of an Indian teaching hospital","volume":"43","author":"Sengupta","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"R19-4-20240903","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R20-4-20240903","doi-asserted-by":"crossref","first-page":"102267","DOI":"10.1016\/j.dsx.2021.102267","article-title":"COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum","volume":"15","author":"Dubey","year":"2021","journal-title":"Diabetes Metab Syndr"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_474_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:42:40Z","timestamp":1787769760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_474_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_474_22","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}